Atrial Fibrillation Market Summary
The atrial fibrillation therapeutics market is expected to increase substantially across the 7MM during the forecast period (2025–2034), driven by major drivers such as the rising prevalent population, technological advancements, and upcoming therapies. In the United States, the estimated prevalence of atrial fibrillation ranges from approximately 2.7 to 6.1 million individuals. In 2024, the United States held a significant share of the overall 7MM atrial fibrillation market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of available treatments, a dominance projected to persist, especially with the potential early introduction of new products.
Currently, RAPIBLYK (landiolol) is the only FDA-approved ultra-short-acting beta-blocker specifically for rapid heart rate control in atrial fibrillation and atrial flutter in critical care, highlighting a significant market opportunity for new therapies. Several leading pharmaceutical companies, including Novartis, HUYABIO International, Bristol Myers Squibb, and Johnson & Johnson, are actively advancing pipelines focused on Factor XIa inhibitors and monoclonal antibodies to address unmet clinical needs and reduce risks associated with current anticoagulant treatments.
Explore DelveInsight’s Full Coverage on the Atrial Fibrillation Market
Atrial Fibrillation Overview
Atrial fibrillation is the most common form of cardiac arrhythmia, caused by abnormal electrical impulses in the atria that lead to rapid and irregular heartbeats. Classified as a tachyarrhythmia, atrial fibrillation can be paroxysmal (lasting less than seven days) or persistent (lasting more than seven days). The irregular rhythm disrupts normal blood flow, increasing the risk of thrombus (blood clot) formation, which can travel to the brain and cause a stroke, making atrial fibrillation the leading cardiac-related cause of stroke. Risk factors include advanced age, hypertension, structural heart or lung disease, congenital heart defects, and excessive alcohol intake. Symptoms range from none to chest pain, palpitations, rapid heartbeat, shortness of breath, dizziness, nausea, sweating, and fatigue. While atrial fibrillation can become a chronic condition, several treatment and risk-reduction strategies exist, including anticoagulants, medications for rate and rhythm control, electrical cardioversion, catheter ablation, and other interventional cardiac procedures aimed at minimizing stroke risk and improving quality of life.
Atrial Fibrillation Diagnosis and Treatment Algorithm
The evaluation of atrial fibrillation begins with a thorough history and physical examination to identify risk factors, comorbidities, and clinical signs such as abnormal heart sounds, elevated jugular venous pressure, pulmonary rales, or signs of heart failure. Diagnostic workup includes blood tests, complete blood count, electrolytes, thyroid function, liver and kidney panels, and imaging studies like echocardiography and chest X-rays to assess cardiac and pulmonary status.
Treatment focuses on three pillars: rate control, rhythm control, and anticoagulation. The choice between rhythm and rate control depends on symptom severity, comorbidities, and the likelihood of successful cardioversion or ablation. Warfarin remains a key anticoagulant for patients at moderate to high risk of thromboembolism, though not all patients are eligible due to contraindications. Antiarrhythmic drugs such as flecainide, sotalol, dofetilide, and off-label agents like amiodarone aim to reduce atrial fibrillation episodes and improve quality of life, potentially reducing the need for long-term anticoagulation in select cases.
Atrial Fibrillation Market Players
Atrial Fibrillation companies include:
- Novartis
- Bristol Myers Squibb
- Johnson & Johnson
- HUYABIO International
- And Others.
Atrial Fibrillation Epidemiology
The epidemiology section of the Atrial Fibrillation market insight report provides historical and projected patient population data across the seven major markets (7MM), supported by key opinion leader perspectives that contextualize observed and anticipated trends. Relevant tables and graphs offer a clear view of prevalence patterns, with disclosed assumptions ensuring transparency in data interpretation.
Key Findings:
- According to recent secondary analyses, the estimated prevalence of atrial fibrillation in the United States ranges from approximately 2.7 to 6.1 million individuals
- According to 2024 data from the National Heart, Lung, and Blood Institute (NHLBI), approximately 2 million adults, representing 6.8% of the population studied, had atrial fibrillation
- In the US, atrial fibrillation prevalence increases significantly with age, affecting just 0.1% of individuals under 55, rising to 3.8% among those aged 60 and older, and reaching approximately 10% in people aged 80 and above
- Secondary analysis indicates an estimated lifetime risk of developing atrial fibrillation affecting approximately 1 in 3 individuals over the age of 45 in the US
- Recent secondary analysis indicates that approximately 1 in every 45 individuals in the UK is currently living with atrial fibrillation
- In Japan, atrial fibrillation prevalence is higher in men than women across all age groups, with prevalence in men at 0.3% (ages 50–59), 2.4% (60–69), and 4.1% (70–79), compared to 0%, 0.3%, and 0.7% respectively among women in the same age brackets
Atrial Fibrillation Market Outlook
The atrial fibrillation therapeutics market is expected to increase further, driven by major drivers such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2025–2034). The treatment landscape includes a variety of pharmacologic and interventional strategies aimed at stroke prevention, heart rate control, and rhythm management. Standard therapies involve anticoagulants such as apixaban and warfarin, beta-blockers like metoprolol, and antiarrhythmics including amiodarone. In critical care settings, the FDA approval of RAPIBLYK (landiolol) introduced a new option for rapid, short-term heart rate control, demonstrating heart rate reduction in 40–90% of patients within 10 minutes, with minimal impact on blood pressure. According to DelveInsight, the atrial fibrillation market in the 7MM is expected to change significantly during the forecast period (2025–2034).
Atrial Fibrillation Recent Developments
- In September 2025, Kardium Inc. received FDA pre-market approval (PMA) for its Globe Pulsed Field System and 510(k) clearance for the Globe Introducer sheath and mapping software, supporting high-density cardiac mapping and single-shot pulmonary vein isolation (PVI) using a single catheter
- In September 2025, Pulse Biosciences received FDA approval for its Investigational Device Exemption (IDE) to start the NANOCLAMP AF study, testing its Nanosecond Pulsed Field Ablation (nsPFA) technology for treating atrial fibrillation
Marketed Atrial Fibrillation Drugs
- RAPIBLYK (landiolol) – AOP Orphan Pharmaceuticals
Landiolol is an ultra-short-acting beta-adrenergic receptor antagonist with a high beta-1 to beta-2 selectivity ratio of 255. It offers a rapid onset of action and effectively lowers heart rate with minimal impact on blood pressure. Primarily intended for acute care settings such as emergency departments, cardiac critical care units, operating rooms, and intensive care, it is used for short-term management rather than chronic treatment of cardiac arrhythmias.
In Europe, landiolol is marketed as RAPIBLOC and approved to treat supraventricular tachycardia, including atrial fibrillation and atrial flutter. In Japan, the same drug is available under the brand name ONOACT, developed and distributed by Ono Pharmaceutical.
In November 2024, AOP Health reported that the US FDA granted regulatory approval for RAPIBLYK (landiolol) for use in hospital critical care settings, covering short-term treatment of supraventricular tachycardia, including atrial fibrillation
The FDA’s approval of RAPIBLYK was based on data from five randomized, double-blind, placebo-controlled trials involving 317 adults with supraventricular tachycardia, with landiolol reducing heart rate in 40–90% of patients within about 10 minutes, compared to just 0–11% in the placebo group
Download the Atrial Fibrillation market report for in-depth insights on pipeline and forecast
Emerging Atrial Fibrillation Drugs
The Atrial Fibrillation market is expected to evolve significantly, supported by an active pipeline of emerging therapies addressing substantial unmet need. Key emerging candidates include milvexian, abelacimab, and HBI-3000, with active development programs targeting Factor XIa inhibition and novel antiarrhythmic mechanisms.
- Milvexian – Bristol Myers Squibb/Johnson & Johnson
Milvexian is an investigational oral anticoagulant developed by Bristol Myers Squibb in collaboration with Janssen, designed as a selective inhibitor of Factor XIa, a key enzyme in the intrinsic coagulation pathway. It is currently being evaluated in the large Phase III LIBREXIA-AF trial, a global, randomized, double-blind study comparing its efficacy and safety to apixaban.
Phase III data from the LIBREXIA-AF trial evaluating milvexian for atrial fibrillation is anticipated by 2027
In May 2023, Bristol Myers Squibb, in collaboration with Janssen Pharmaceuticals, announced that the US FDA had granted Fast Track Designation for all three of milvexian’s investigational indications, including atrial fibrillation
- Abelacimab – Novartis
Abelacimab is a fully human, highly selective monoclonal antibody that binds tightly to Factor XI, effectively blocking its activation and preventing formation of its active form, Factor XIa, mimicking the protective effect seen in individuals with natural Factor XI deficiency. It has received Fast Track Designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation from the US FDA and is currently being investigated in Phase III.
Novartis is expected to pursue regulatory filing for abelacimab in 2027, following completion of ongoing Phase III trials
In February 2025, Novartis reported an agreement to acquire Anthos Therapeutics, the clinical-stage company developing abelacimab
In June 2023, Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) granted approval to launch the Phase III LILAC-TIMI 76 trial, evaluating abelacimab in atrial fibrillation patients unsuitable for currently available anticoagulants
- HBI-3000 – HUYABIO International
HBI-3000 is a multi-ion channel blocker exhibiting in vitro inhibition of INa-Peak, INa-Late, ICa-L, and IKr, being evaluated for the conversion of recent-onset atrial fibrillation. It is currently in Phase II development.
In April 2025, HUYABIO International unveiled new patient data on HBI-3000 demonstrating strong antiarrhythmic potential, excellent tolerability, and a distinctive mechanism that minimizes QT prolongation, showcased at the Heart Rhythm Annual Meeting
In November 2024, HUYABIO International disclosed new patient-level data highlighting the clinical potential of HBI-3000, characterized by a distinctive protective pharmacological profile
Atrial Fibrillation Drugs Uptake
This section examines the sales uptake of potential atrial fibrillation drugs launched or anticipated to launch between 2020 and 2034, estimating market penetration across countries and evaluating their impact within and across therapeutic classes and segments. It also addresses the financial and regulatory factors contributing to the probability of success of drugs in the atrial fibrillation market.
Emerging therapies are analyzed on the basis of safety and efficacy in randomized clinical trials, order of market entry, broader market dynamics, and the degree to which they address unmet need within the atrial fibrillation treatment landscape.
Get a Detailed Analysis of Market Access and Reimbursement for Atrial Fibrillation
Conclusion
The Atrial Fibrillation market is poised for meaningful growth through 2034, supported by an aging population, rising prevalence, and continued advancements in therapeutic innovation. While anticoagulants, rate-control agents, and rhythm-management strategies remain the cornerstone of treatment, persistent unmet needs, particularly in early detection, stroke prevention, and reducing bleeding risks associated with current anticoagulants, are driving development of next-generation agents with novel mechanisms. Promising pipeline candidates such as milvexian, abelacimab, and HBI-3000, alongside recent device advancements from Kardium Inc. and Pulse Biosciences, have the potential to reshape the treatment landscape and enhance patient outcomes. As research progresses and access to innovative therapies and technologies expands, the Atrial Fibrillation market is expected to witness significant transformation, creating new opportunities for stakeholders while addressing the long-term challenges associated with this widespread condition.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
